Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

W. Eiermann · SciRah

Researcher profile · Semantic Scholar

W. Eiermann

Share profile

W. Eiermann — researcher profile on SciRah

h-index: 64
Works: 306
Citations: 29K

Most-cited papers

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
P. Cortazar, Li-Jun Zhang, M. Untch, K. Mehta +33 more
2014The Lancet4,280 citations Open access
Semantic Scholar
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
G. von Minckwitz, M. Untch, J. Blohmer, S. Costa +13 more
2012Journal of Clinical Oncology2,454 citations
Semantic Scholar
“Talazoparib for Advanced Germline BRCA-mutated Breast Cancer”
J. Litton, H. Rugo, J. Ettl, S. Hurvitz +14 more
2018New England Journal of Medicine1,768 citations Open access
Semantic Scholar
Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial.
J. Vaidya, F. Wenz, M. Bulsara, J. Tobias +25 more
2014The Lancet818 citations Open access
Semantic Scholar
Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer
M. Kaufmann, G. von Minckwitz, Elefhterios P. Mamounas, D. Cameron +15 more
2012Annals of Surgical Oncology470 citations
Semantic Scholar
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
L. Gianni, W. Eiermann, V. Semiglazov, A. Lluch +16 more
2014The Lancet Oncology467 citations
Semantic Scholar
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
J. Litton, S. Hurvitz, L. Mina, H. Rugo +16 more
2020Annals of Oncology386 citations Open access
Semantic Scholar
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study
E. Perez, C. Barrios, W. Eiermann, M. Toi +11 more
2016Journal of Clinical Oncology380 citations Open access
Semantic Scholar
Response-guided neoadjuvant chemotherapy for breast cancer.
G. von Minckwitz, J. Blohmer, S. Costa, C. Denkert +15 more
2013Journal of Clinical Oncology351 citations Open access
Semantic Scholar
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
M. Gnant, B. Mlineritsch, H. Stoeger, G. Luschin-Ebengreuth +21 more
2015Annals of Oncology306 citations Open access
Semantic Scholar
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.
J. Bergh, P. Jönsson, E. Lidbrink, M. Trudeau +5 more
2012Journal of Clinical Oncology275 citations Open access
Semantic Scholar
Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial
J. Vaidya, M. Bulsara, M. Baum, F. Wenz +35 more
2020British medical journal257 citations Open access
Semantic Scholar
Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study
A. Prat, G. Bianchini, Marlène Thomas, A. Belousov +12 more
2014Clinical Cancer Research234 citations Open access
Semantic Scholar
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.
C. Denkert, S. Loibl, B. Müller, H. Eidtmann +16 more
2013Annals of Oncology229 citations Open access
Semantic Scholar
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial
J. Forbes, I. Šestak, A. Howell, B. Bonanni +11 more
2016The Lancet181 citations Open access
Semantic Scholar
Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer
G. von Minckwitz, W. Schmitt, S. Loibl, B. Müller +17 more
2013Clinical Cancer Research155 citations Open access
Semantic Scholar
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
W. Eiermann, M. Rezai, S. Kümmel, T. Kühn +12 more
2012Annals of Oncology144 citations Open access
Semantic Scholar
Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial
J. Ettl, R. G. W. Quek, Kyung-Hun Lee, H. Rugo +14 more
2018Annals of Oncology137 citations Open access
Semantic Scholar
HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials
M. Press, G. Sauter, M. Buyse, Hélène Fourmanoir +16 more
2016Journal of Clinical Oncology127 citations Open access
Semantic Scholar
13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013).
M. Untch, B. Gerber, N. Harbeck, C. Jackisch +27 more
2013Breast Care125 citations Open access
Semantic Scholar
Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients
S. Hurvitz, D. Betting, H. Stern, E. Quinaux +20 more
2012Clinical Cancer Research104 citations Open access
Semantic Scholar
Effect of Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy on Local Recurrence and Survival
J. Vaidya, M. Bulsara, C. Saunders, H. Flyger +35 more
2020JAMA Oncology102 citations Open access
Semantic Scholar
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE
E. Perez, C. Barrios, W. Eiermann, M. Toi +11 more
2019Cancer101 citations Open access
Semantic Scholar
Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC)
P. Cortazar, Li-Jun Zhang, M. Untch, K. Mehta +34 more
201297 citations
Semantic Scholar
Phase III, randomized study of trastuzumab emtansine (T-DM1) {+/-} pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.
P. Ellis, C. Barrios, W. Eiermann, M. Toi +9 more
201591 citations
Semantic Scholar
Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator
Philip Vlaicu, Philipp Mertins, T. Mayr, P. Widschwendter +5 more
2013BMC Cancer85 citations Open access
Semantic Scholar
PTK 7 Is a Transforming Gene and Prognostic Marker for Breast Cancer and Nodal Metastasis Involvement
S. Gärtner, A. Gunesch, T. Knyazeva, Petra Wolf +5 more
2014PLoS ONE71 citations Open access
Semantic Scholar
Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer.
J. Albanell, C. Svedman, J. Gligorov, S. Holt +5 more
2016European Journal of Cancer69 citations Open access
Semantic Scholar
PTEN loss is associated with worse outcome in HER2-amplified breast cancer patients but is not associated with trastuzumab resistance
H. Stern, H. Gardner, T. Burzykowski, W. Elatre +15 more
2015Clinical Cancer Research67 citations Open access
Semantic Scholar
Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
J. Mackey, T. Pieńkowski, J. Crown, S. Sadeghi +15 more
2016Annals of Oncology64 citations Open access
Semantic Scholar
Pride, Prejudice, or Science: Attitudes Towards the Results of the TARGIT-A Trial of Targeted Intraoperative Radiation Therapy for Breast Cancer
J. Vaidya, M. Bulsara, F. Wenz, D. Joseph +11 more
2015International Journal of Radiation Oncology, Biology, Physics63 citations Open access
Semantic Scholar
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
E. Perez, S. de Haas, W. Eiermann, C. Barrios +10 more
2019BMC Cancer61 citations Open access
Semantic Scholar
Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting
J. Blohmer, M. Rezai, S. Kümmel, T. Kühn +5 more
2013Journal of Medical Economics58 citations Open access
Semantic Scholar
Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation
J. Litton, H. Rugo, J. Ettl, S. Hurvitz +13 more
201857 citations
Semantic Scholar
A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52)
G. von Minckwitz, B. Conrad, T. Reimer, T. Decker +16 more
2015Cancer53 citations Open access
Semantic Scholar
New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer
J. Vaidya, M. Bulsara, M. Baum, F. Wenz +35 more
2021British Journal of Cancer46 citations Open access
Semantic Scholar
Breast cancer, early stage
Tony S. K. Mok, L. Paz-Ares, Y.-L. Wu, S. Novello +496 more
201245 citations Open access
Semantic Scholar
BRCA2 Mutations and Triple-Negative Breast Cancer
Peter Meyer, Katharina Landgraf, Bernhard Högel, W. Eiermann +1 more
2012PLoS ONE43 citations Open access
Semantic Scholar
Abstract S1-11: Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC)
P. Cortazar, Li-Jun Zhang, M. Untch, K. Mehta +34 more
201242 citations
Semantic Scholar
PTK7 expression in triple-negative breast cancer.
B. Ataseven, R. Angerer, R. Kates, A. Gunesch +5 more
2013Anticancer Research37 citations
Semantic Scholar
Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design.
W. Eiermann, J. Bergh, F. Cardoso, P. Conte +13 more
2012Breast35 citations Open access
Semantic Scholar
Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines
M. Press, J. Seoane, C. Curtis, E. Quinaux +13 more
2018JAMA Oncology34 citations Open access
Semantic Scholar
Abstract S4-2: Targeted intraoperative radiotherapy for early breast cancer: TARGIT-A trial- updated analysis of local recurrence and first analysis of survival
J. Vaidya, F. Wenz, M. Bulsara, D. Joseph +25 more
201231 citations
Semantic Scholar
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
H. Rugo, J. Ettl, S. Hurvitz, A. Gonçalves +15 more
2019JNCI Cancer Spectrum30 citations Open access
Semantic Scholar
Locoregional treatments for triple-negative breast cancer.
W. Eiermann, K. Vallis
2012Annals of Oncology29 citations Open access
Semantic Scholar
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study.
H. Au, W. Eiermann, N. Robert, T. Pieńkowski +16 more
2013The Oncologist25 citations Open access
Semantic Scholar
Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer.
L. Gianni, W. Eiermann, V. Semiglazov, A. Manikhas +15 more
201322 citations
Semantic Scholar
HER2/neu, Topoisomerase 2a, Estrogen and Progesterone Receptors: Discordance between Primary Breast Cancer and Metastatic Axillary Lymph Node in Expression and Amplification Characteristics
B. Ataseven, D. Gologan, A. Gunesch, V. Kehl +3 more
2012Breast Care21 citations Open access
Semantic Scholar
Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
S. Kümmel, S. Paepke, J. Huober, C. Schem +15 more
2017European Journal of Cancer19 citations
Semantic Scholar
A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA).
J. Litton, J. Blum, Y. Im, Miguel Martín +8 more
201517 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Blohmer×14
Invite
J. Blohmer — researcher profile on SciRah
Miguel Martín×12
Invite
Miguel Martín — researcher profile on SciRah
S. Loibl×10
Invite
S. Loibl — researcher profile on SciRah
H. Eidtmann×10
Invite
H. Eidtmann — researcher profile on SciRah

G. von Minckwitz

×10

Invite

G. von Minckwitz — researcher profile on SciRah

T. Pieńkowski×10

Invite

T. Pieńkowski — researcher profile on SciRah

Invite

B. Gerber — researcher profile on SciRah

Invite

C. Jackisch — researcher profile on SciRah

Invite

M. Untch — researcher profile on SciRah

Invite

Y. Im — researcher profile on SciRah

Invite

J. Vaidya — researcher profile on SciRah

Invite

J. Crown — researcher profile on SciRah